Sanofi continues to dominate Russian insulin glargine public procurements

Russian drugmaker Geropharm once again failed to challenge the patent for Toujeo (long-acting insulin glargine) produced by the French pharma major Sanofi (Euronext: SAN), reports The Pharma Letter’s local correspondent.

Geropharm has been trying to challenge the patent for this type of insulin for six years. The company has registered an analogue, but so far it can only produce it in Kazakhstan, since Sanofi has a patent for the original product in Russia.

Sanofi initially launched the single-strength insulin glargine under the Lantus Solostar brand. After the patent expired in 2012, the company registered the drug in a different concentration under the brand name Toujeo, pre-patenting it until 2031.